TransMedics Group, Inc. (TMDX) witnessed a significant surge in its stock price, soaring 6.77% in the pre-market session on Friday. This impressive rally was fueled by the company's exceptional fourth-quarter 2024 financial results and a robust outlook for the year 2025.
The medical technology company reported better-than-expected earnings and revenue for the fourth quarter. Earnings per share came in at $0.19, surpassing analysts' estimates of $0.18. Revenue skyrocketed 49.83% year-over-year to $121.62 million, significantly exceeding the consensus estimate of $110.29 million.
TransMedics Group's strong performance was driven by robust demand for its products and services, as well as operational efficiency and improved profitability. The company reported a gross margin of 59% and achieved positive income from operations and net income, further bolstering investor confidence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.